Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations
A phase 1/2 trial of Silevertinib in non-small-cell lung cancer and small-cell lung cancer, run by Black Diamond Therapeutics, Inc., active and no longer recruiting.
Overview
Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations is a phase 1/2 interventional study registered as NCT05256290 by Black Diamond Therapeutics, Inc., with 200 participants planned, started 2022-03-31 and due to reach its primary completion in 2025-11-03. Interventions recorded: silevertinib (BDTX-1535) monotherapy. Conditions listed: Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Cancer. No results are recorded here; the registry entry is the source.